Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KALV |
---|---|---|
09:32 ET | 3319 | 11.47 |
09:34 ET | 200 | 11.68 |
09:36 ET | 244 | 11.58 |
09:41 ET | 400 | 11.48 |
09:45 ET | 100 | 11.495 |
09:50 ET | 1300 | 11.5 |
09:52 ET | 700 | 11.56 |
09:54 ET | 200 | 11.545 |
09:59 ET | 200 | 11.57 |
10:03 ET | 484 | 11.61 |
10:06 ET | 200 | 11.5501 |
10:14 ET | 700 | 11.6 |
10:15 ET | 100 | 11.61 |
10:17 ET | 700 | 11.68 |
10:30 ET | 604 | 11.63 |
10:32 ET | 457 | 11.605 |
10:35 ET | 4231 | 11.535 |
10:37 ET | 100 | 11.54 |
10:39 ET | 200 | 11.57 |
10:42 ET | 400 | 11.59 |
10:44 ET | 100 | 11.55 |
10:48 ET | 100 | 11.545 |
10:53 ET | 100 | 11.53 |
10:55 ET | 100 | 11.5 |
11:02 ET | 500 | 11.49 |
11:09 ET | 700 | 11.435 |
11:13 ET | 500 | 11.39 |
11:18 ET | 500 | 11.37 |
11:22 ET | 476 | 11.38 |
11:24 ET | 1420 | 11.36 |
11:26 ET | 300 | 11.41 |
11:27 ET | 100 | 11.39 |
11:29 ET | 294 | 11.395 |
11:31 ET | 100 | 11.42 |
11:36 ET | 209 | 11.46 |
11:44 ET | 100 | 11.495 |
11:45 ET | 660 | 11.495 |
11:47 ET | 100 | 11.495 |
11:54 ET | 534 | 11.47 |
11:58 ET | 800 | 11.56 |
12:02 ET | 100 | 11.555 |
12:03 ET | 100 | 11.56 |
12:12 ET | 100 | 11.555 |
12:14 ET | 200 | 11.58 |
12:18 ET | 438 | 11.594 |
12:20 ET | 100 | 11.595 |
12:23 ET | 1674 | 11.57 |
12:27 ET | 800 | 11.55 |
12:30 ET | 200 | 11.55 |
12:32 ET | 800 | 11.52 |
12:36 ET | 600 | 11.54 |
12:38 ET | 100 | 11.56 |
12:39 ET | 100 | 11.55 |
12:43 ET | 200 | 11.56 |
12:45 ET | 100 | 11.6 |
12:52 ET | 100 | 11.64 |
12:54 ET | 100 | 11.64 |
12:56 ET | 100 | 11.64 |
12:57 ET | 100 | 11.64 |
12:59 ET | 300 | 11.64 |
01:01 ET | 200 | 11.64 |
01:06 ET | 450 | 11.67 |
01:10 ET | 100 | 11.67 |
01:17 ET | 100 | 11.655 |
01:19 ET | 100 | 11.655 |
01:26 ET | 900 | 11.685 |
01:28 ET | 200 | 11.68 |
01:30 ET | 200 | 11.68 |
01:33 ET | 200 | 11.72 |
01:35 ET | 1000 | 11.76 |
01:37 ET | 700 | 11.74 |
01:39 ET | 200 | 11.72 |
01:42 ET | 500 | 11.68 |
01:46 ET | 100 | 11.68 |
01:50 ET | 100 | 11.685 |
01:55 ET | 1011 | 11.75 |
01:57 ET | 500 | 11.74 |
02:00 ET | 1730 | 11.684 |
02:04 ET | 100 | 11.685 |
02:09 ET | 200 | 11.66 |
02:11 ET | 200 | 11.65 |
02:13 ET | 100 | 11.68 |
02:22 ET | 200 | 11.68 |
02:24 ET | 200 | 11.68 |
02:27 ET | 100 | 11.69 |
02:29 ET | 3653 | 11.685 |
02:31 ET | 572 | 11.67 |
02:33 ET | 200 | 11.635 |
02:36 ET | 219 | 11.625 |
02:40 ET | 600 | 11.57 |
02:42 ET | 100 | 11.59 |
02:44 ET | 524 | 11.57 |
02:45 ET | 423 | 11.54 |
02:47 ET | 954 | 11.56 |
02:51 ET | 100 | 11.535 |
02:54 ET | 1900 | 11.53 |
02:56 ET | 300 | 11.54 |
03:00 ET | 100 | 11.54 |
03:02 ET | 900 | 11.55 |
03:03 ET | 100 | 11.59 |
03:05 ET | 800 | 11.55 |
03:07 ET | 200 | 11.54 |
03:12 ET | 100 | 11.53 |
03:16 ET | 1300 | 11.6 |
03:20 ET | 100 | 11.6 |
03:21 ET | 3577 | 11.56 |
03:23 ET | 1300 | 11.59 |
03:25 ET | 667 | 11.6 |
03:27 ET | 384 | 11.59 |
03:30 ET | 384 | 11.605 |
03:34 ET | 1300 | 11.56 |
03:36 ET | 1200 | 11.57 |
03:38 ET | 500 | 11.56 |
03:39 ET | 350 | 11.56 |
03:41 ET | 2928 | 11.61 |
03:43 ET | 300 | 11.58 |
03:45 ET | 200 | 11.595 |
03:48 ET | 2184 | 11.585 |
03:50 ET | 1300 | 11.56 |
03:52 ET | 1300 | 11.54 |
03:54 ET | 55356 | 11.485 |
03:56 ET | 7134 | 11.45 |
03:57 ET | 52812 | 11.4225 |
03:59 ET | 18782 | 11.44 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kalvista Pharmaceuticals Inc | 482.6M | -3.6x | --- |
Mereo BioPharma Group PLC | 391.3M | -10.8x | --- |
Third Harmonic Bio Inc | 474.3M | -12.3x | --- |
ACELYRIN Inc | 474.1M | -0.4x | --- |
Nkarta Inc | 518.7M | -3.1x | --- |
Humacyte Inc | 440.6M | -3.5x | --- |
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $482.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 42.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.91 |
EPS | $-3.14 |
Book Value | $4.71 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.